


FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office 	Docket No.: AERO1210-2	Application No.: 10/820,559
	Applicants: Pan, et al.	Confirmation No.:
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: April 8, 2004	Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
FH	A	5,986,059	11/16/99	Shanafelt, et al.	530	351	
FH	B	6,130,318	10/10/00	Wild, et al.	530	351	

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	C	WO 987/03654	1/29/98	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

FH	D	Kreitman, et al., "Site-Specific Conjugation to Interleukin 4 Containing Mutated Cysteine Residues Produces Interleukin 4-Toxin Conjugates with Improved Binding and Activity," <i>Biochem.</i> 33:11637-11644, (1994).

EXAMINER GT6449734.1 356897-160 /Fozia Hamud/	DATE CONSIDERED 01/08/2007
---	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box C

+

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application No.	
		Filing Date:	April 8, 2004
		First Named Inventor	Pan
		Group Art Unit	1647
		Examiner Name	unassigned
Sheet 1 of 1	Attorney Docket No.	03-839-C	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
FH	1	YING S., ET AL., "Expression of IL-4 and IL-5 mRNA and Protein Product by CD4 ⁺ and CD8 ⁺ T Cells, Eosinophils, and Mast Cells in Bronchial Biopsies Obtained from Atopic and Nonatopic (Intrinsic) Asthmatics," <i>J. Immunol.</i> , 158(7):3539-3544 (1997 Apr 1)	
FH	2	HUANG S., ET AL., "IL-13 Expression at the Sites of Allergen Challenge in Patients with Asthma," <i>J. Immunol.</i> , 155(5):2688-2694 (1995 Sep 1)	
FH	3	ZHU Z., ET AL., "Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production," <i>J. Clin. Invest.</i> , 103(6):779-788 (March 1999)	
FH	4	HENDERSON W., ET AL., "Soluble IL-4 Receptor Inhibits Airway Inflammation Following Allergen Challenge in a Mouse Model of Asthma," <i>J. Immunol.</i> , 164(2):1086-1095 (2000 Jan 15)	
FH	5	LEVENS JM, ET AL., "Micro-environmental factors in the survival of human B-lymphoma cells," <i>Cell Death Differ.</i> , 7:59-69 (2000)	
FH	6	MYERS J., ET AL., "Growth Stimulation of Human Head and Neck Squamous Cell Carcinoma Cell Lines by Interleukin 4," <i>Clin Cancer Res.</i> , 2:127-135 (January 1996)	
FH	7	NEWCOM SR, ET AL., "Interleukin-4 Is an Autocrine Growth Factor Secreted by the L-428 Reed-Sternberg Cell," <i>Blood</i> , 79(1):191-197 (January 1 1992)	
FH	8	GEE K., ET AL., "Differential Effect of IL-4 and IL-13 on CD44 Expression in the Burkitt's Lymphoma B Cell Line BL30/B95-8 and in Epstein-Barr Virus (EBV) Transformed Human B Cells; Loss of IL-13 Receptors on Burkitt's Lymphoma B Cells," <i>Cell Immunol.</i> , 211:131-142 (2001)	
FH	9	KRYWORUCHKO M., ET AL., "Regulation of CD44-Hyaluronan Interactions in Burkitt's Lymphoma and Epstein-Barr Virus-Transformed Lymphoblastoid B Cells by PMA and Interleukin-4," <i>Cell Immunol.</i> , 194:54-66 (1999)	
FH	10	KRUSE N., ET AL., "Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement," <i>Embo J.</i> , 11(9):3237-3244 (1992)	
FH	11	TONY H., ET AL., "Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency," <i>Eur. J. Biochem.</i> , 225:659-665 (1994)	

Examiner Signature	/Fozia Hamud/	Date Considered	01/08/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231